Tango Therapeutics ($TNGX) Insider Trading & Smart Money Activity
Tango Therapeutics, Inc. ($TNGX) has 3 insider trades, 3 13F position changes and 6 analyst ratings on file. In the last 12 months on the open market, no insider bought and 2 insiders sold ($859.41K), net -$859.41K.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 2
- Net insider $ (12 mo)
- -$859.41K
- Congress trades (12 mo)
- 0
- 13F moves on file
- 3
- Analyst ratings on file
- 6
TNGX insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 1 |
| Q2 2026 | 0 | 0 | 0 / 0 | 1 / 1 |
| Q3 2026 | 0 | 1 · $198.61K | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 1 · $660.80K | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All TNGX insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Crystal AdamPresident, R&D | Sell (Open-market sale) 10b5-1 | 27K sh | $660.80K | -7.7% | — | |||||
| Insider | Newcomb JessicaPrincipal Accounting Officer | Sell (Open-market sale) 10b5-1 | 8.20K sh | $198.61K | -4.3% | — | |||||
| Analyst | Canaccord Genuity | Reiterates to buy | PT $46 | -8.0% | -20.6% | Read | |||||
| Analyst | Jefferies | Raises to buy | PT $60 | -4.9% | -15.1% | Read | |||||
| Insider | Robert Azelby | Buy (Grant or award) | 35.91K sh | +10.4% | -3.4% | Read | |||||
| Analyst | Canaccord Genuity | Reiterates to buy | PT $42 | -6.2% | -4.9% | Read | |||||
| Analyst | Canaccord Genuity | Reiterates to buy | PT $42 | -6.2% | -4.9% | Read | |||||
| Analyst | HC Wainwright | Reiterates to buy | PT $66 | +1.9% | -3.3% | — | |||||
| Analyst | HC Wainwright | Reiterates to buy | PT $66 | +1.9% | -3.3% | Read | |||||
| 13F | Rtw Investments | Added | +11.81M sh | $433.07M | -1.6% | +60.0% | Read | ||||
| 13F | Farallon Capital Management | Reduced | -3.96M sh | $296.21M | -1.6% | +60.0% | — | ||||
| 13F | Avoro Capital Advisors | Sold out | -545K sh | +0.6% | +50.9% | +98.8% | Read |
1W / 1M / 6M = how TNGX moved from the trade or filing date.
Insider trading in TNGX: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Crystal Adam | President, R&D | 1 | -$660.80K | Oct 1, 2026 | |
| Newcomb Jessica | Principal Accounting Officer | 1 | -$198.61K | Sep 22, 2026 | |
| Robert Azelby | 1 | — | Jun 19, 2026 |
Institutions moving TNGX (13F)
Analyst ratings on TNGX
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Reiterates | buy | $46 | -8.0% | -20.6% | Read | ||
| Jefferies | Raises | buy | $60 | -4.9% | -15.1% | Read | ||
| Canaccord Genuity | Reiterates | buy | $42 | -6.2% | -4.9% | Read | ||
| Canaccord Genuity | Reiterates | buy | $42 | -6.2% | -4.9% | Read | ||
| HC Wainwright | Reiterates | buy | $66 | +1.9% | -3.3% | — | ||
| HC Wainwright | Reiterates | buy | $66 | +1.9% | -3.3% | Read |
Frequently asked questions
Are TNGX insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 2 insiders made 2 open-market sales worth $859.41K, a net -$859.41K.
What is the latest insider trade in TNGX?
Crystal Adam, President, R&D filed a sell (open-market sale) of 27K sh worth $660.80K on Oct 1, 2026.
Which institutions changed their TNGX positions?
Recent 13F filers moving the stock include Rtw Investments, Farallon Capital Management and Avoro Capital Advisors.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.